ZENTALIS PHARMACEUTICALS INCZNTL
ASignal's systematic analysis rates ZNTL as Bearish.
Reflects the latest available analysis · analyzed Oct 9, 2026
The case on ZNTL
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Current price near lower Bollinger Band, indicating potential reversal
- Low debt-to-equity ratio (0.26x) suggests strong financial health
- High cash position with $174.61M in total cash
- Current ratio of 4.82x indicates strong liquidity
- Negative MACD and declining momentum (MACD < signal line)
- Negative price momentum (-0.07)
- Negative return on equity (-66.75%) and return on assets (-33.15%)
- Negative operating and free cash flow
- No Reddit mentions, suggesting low retail interest
- Only two news sources (Benzinga, Yahoo), limited news coverage
See the full verdict on ZNTL
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes ZNTL
Most investors never get a second opinion, let alone several. ASignal runs ZNTL past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.